We have undertaken a genome-wide single nucleotide polymorphism (SNP) array analysis of 41 chronic myeloid leukemia (CML) patients. In total, 44 regions of uniparental disomy (UPD) 43 Mb were identified in 24 of 32 patients in chronic phase (CP), and 21 regions of UPD 43 Mb were identified in 13 of 21 patients in blast crisis (BC). Chromosome 8 had the highest frequency of UPD regions in both CP and BC samples. Eight recurrent regions of UPD were observed among the 41 patients, with chromosome 8 showing the highest frequency. Ten regions of copy number change (CNC) 43 Mb were observed in 4 of 21 patients in BC, whereas none were observed in CP. We have identified several recurrent regions of UPD and CNC in CML that may be of pathogenetic importance. Overrepresentation of genomic aberrations (UPD and copy number gain) mapping to chromosome 8 was observed. Selected candidate genes mapping within the aberrant genomic regions were sequenced and mutation of the TP53 gene was observed in one case in BC and of the ASXL1 gene in 6 of 41 cases in CP or BC. Mutation of ASXL1 represents an important new molecular abnormality in CML.
Introduction
Chronic myeloid leukemia (CML) is a clonal disorder of the hematopoietic stem cell that typically evolves from an initial chronic phase (CP) to a terminal acute phase termed blast crisis (BC) that resembles acute leukemia. 1 In some patients, a transitional accelerated phase precedes BC. 1 The Philadelphia chromosome (Ph1), or t(9;22) encoding the BCR/ABL fusion oncoprotein, is the hallmark of CML. 2, 3 Until recently, transition to BC was the inevitable outcome of CML except in a cohort of patients receiving allogeneic bone marrow transplants early in the CP CML. 1 The development of the BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis, East Hanover, NJ, USA) has revolutionized the treatment of CML. 4 Imatinib is now established as the standard first-line therapy for patients with newly diagnosed CP CML. 5 Virtually all patients treated with this drug in the early stages of CML respond, but in advanced phases the leukemia usually becomes resistant within months. 6, 7 Therefore, leukemic transformation remains a serious clinical problem in CML and is seen both in the small group of patients not treated with imatinib and also in those who have become resistant to the drug. 6, 7 Although it is recognized that cytogenetic and molecular changes occur in the majority of CML patients during evolution to BC, the molecular events responsible for leukemic transformation remain unclear. It has been suggested that BCR/ABL may have a direct or an indirect role in promoting genomic instability and 60-80% of patients with CML develop additional nonrandom chromosomal abnormalities involving chromosomes 8, 17, 19 and 22. 8 In addition, marker chromosomes arising from complex chromosome rearrangements are present in B20% of the BC CML cases and may remain unresolved by banding analysis. Some combinations, such as trisomy 8, double Ph chromosome and i(17q), are more frequent than others; however, neither the presumed order of appearance nor the combination itself seems to have a clear impact on the prognosis of BC CML. 8 We have shown that telomere shortening and diminishing levels of hTERT are associated with disease evolution in CML. 9, 10 Mutation of the tumor suppressor gene p53 is detected in B25-30% of CML-myeloid BC, 11 whereas B50% of the patients with lymphoid BC present a homozygous deletion of the INK4A/ARF gene. 12 Most recently, it has been shown that the loss of the IKAROS (IKZF1) gene is an important event in the development of lymphoid BC in CML and IKAROS is deleted in B80% of such patients. 13 At the molecular level, BC CML is a heterogeneous disease. 12 It is essential to the management and treatment of CML to understand the biology of CML transformation. 12 We have applied single nucleotide polymorphism (SNP) array analysis to the study of CML to achieve a better understanding of the pathogenic mechanisms central to disease heterogeneity and progression. To study disease progression without the complicating factor of imatinib treatment, we have performed this study exclusively on CML samples obtained in the immediate 'preimatinib era'. The identification of recurrent regions of uniparental disomy (UPD), genomic deletions, amplifications or other cryptic rearrangements in CML during disease evolution would clearly be of great value not only as potential new prognostic indicators, but also as clues to the location of oncogenes or tumor suppressor genes central to leukemic transformation.
Patients and methods

Patients and samples
Forty-one patients with CML were included in this study. A total of 53 bone marrow or peripheral blood samples were obtained from them, of which 32 were from patients in CP and 21 from patients in BC at the time of investigation. Paired (sequential) samples obtained in CP and also at BC phase were available for 12 of these 41 patients. None of the CML patients included in this study were being treated with imatinib at the time the samples were taken. The samples from CML patients were obtained from two sources: Oxford and Liverpool (UK). The study was approved by the ethics committees of the institutes involved (Oxford C00.196, Liverpool 02/11/230/A) and informed consent was obtained. The patient karyotypes are shown in Supplementary Table  1 . The BCR-ABL mRNA transcript level was measured in some patients by quantitative real-time PCR as previously described, 14 using ABL as the control gene, in line with recent recommendations. 15 All BCR-ABL/ABL ratios were obtained from RNA extracted from the same population of cells used for SNP analysis.
DNA preparation
Bone marrow aspirates were collected in PBS supplemented with 2 mM EDTA and peripheral blood samples were collected in EDTA tubes. Mononuclear cell fractions were obtained from bone marrow samples by Histopaque density gradient centrifugation (Sigma-Aldrich, Dorset, UK). For patients in BC, the leukemic blast fraction (mononuclear fraction) was separated by Histopaque density gradient centrifugation from peripheral blood samples. Genomic DNA was isolated by phenol/chloroform extraction using standard methods and evaluated for quality and concentration using an ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
SNP mapping assay
The SNP mapping assay was carried out according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Briefly, 250 ng DNA were digested with HindIII, ligated to the adaptor and amplified by PCR using a single primer. PCR products were purified with the DNA amplification clean-up kit (Clontech, Mountain View, CA, USA) and the amplicons were quantified. Purified amplicons (40 mg) were fragmented, end-labeled and hybridized to a Genechip Mapping 50K HindIII array at 48 1C for 16-18 h in a Hybridization Oven 640 (Affymetrix). After washing and staining in a Fluidics Station 450 (Affymetrix), the arrays were scanned with a GeneChip Scanner 3000 (Affymetrix). 16 
SNP array data analysis
Cell intensity calculations and scaling were carried out using GeneChip Operating Software. Data were analyzed using GeneChip Genotyping Analysis Software Version 4.0 (Affymetrix) and CNAG software version 2.0. Quality control was performed within the genotyping software after scaling the signal intensities of all arrays to a target of 100. DNA copy number was analyzed with both the chromosome copy number tool (CNAT) version 3.0 and CNAG version 2.0. CNAT compares obtained SNP hybridization signal intensities with SNP intensity distributions of a reference set from more than 100 healthy individuals of different ethnicity. For analysis with CNAG, we used a pool of 45 healthy controls included in the study as a reference set. 16 
Mutational analysis
Mutational analysis was carried out on selected candidate genes mapping within the aberrant genomic regions identified in this study. Sequences spanning exons 5-8 of TP53 were amplified from CP and BC CML DNA samples by PCR in two cases (patients 12 and 40) identified with a deletion at 17p13.3-p11 by SNP analysis. The primers and amplifications conditions were as previously published. 17 Sequences spanning exons 1-7 of IKAROS (IKZF1) were amplified from CP CML DNA samples by PCR in two cases (patients 20a and 41) identified with a UPD or deletion at 7p13-q11.2, respectively, by SNP analysis. Primers and amplifications conditions were as previously published. 13 Sequences spanning exon 12 of the ASXL1 (additional sex combs 1) gene were amplified from all patient DNA samples using PCR. All previously reported mutations of ASXL1 in hematological malignancies were found exclusively in exon 12 of the gene. 18, 19 Primers and amplifications conditions were as previously published. 19 PCR products were purified and directly sequenced using BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 Genetic analyzer (Applied Biosystems). Sequence data was analyzed using Sequence Analysis 1.6.0 (Informagen, Greenland, NH, USA) and Mutation Surveyor v3.25 (Softgenetics, State College, PA, USA).
Results
Quality control of SNP genotype arrays and regions of UPD
The accuracy of whole-genome sampling analysis was determined using GeneChip Operating Software. The mean call rate of all the CML patient samples was 95.76%.
Regions of UPD were defined as continuous stretches of homozygous SNP calls 43 Mb without copy number loss. 20 We observed a total of 32 regions of UPD in 23 of 45 healthy control subjects dispersed across the genome on 15/22 chromosomes (Supplementary Table 2 ). For the patients, we report only those regions of UPD not observed in any of our group of 45 normal controls or in normal healthy control subjects reported in the literature. 20, 21 A total of 65 regions of UPD 43 Mb were detected in 29 of 41 patients, dispersed on 17/22 chromosomes (Supplementary Table 3 , Figure 1 ). Differences in the number of UPDs on each chromosome was significant for chromosome 8 (CP versus controls; P ¼ 0.019). In the CP samples, 44 regions of UPD 43 Mb were identified in 24 of 32 patients. In the BC samples, 21 regions of UPD 43Mb were identified in 13 of 21 patients. In both CP and BC samples, chromosome 8 had the highest frequency of UPD regions, with a total of 14. Chromosomes 2 and 4 also showed a high frequency of UPDs, with a total of 10 and 8, respectively.
Recurrent regions of UPD
Eight regions of UPD 43 Mb were seen in two or more cases in the group of CML patient samples (including CP and BC phase): 2q21.3-q22.1 (three patients), 2q32.3-q33.1 (two patients), 4p15.1 (three patients), 7q22.1-q22.3 (two patients), 8p23.1 (two patients), 8q11.21-q11.22 (two patients), 8q23.2-q23.3 (five patients) and 12p11.21-q12 (two patients). The sizes of these recurrent regions of UPD and the genes that map within them are shown in Table 1 .
Paired sample analysis
Paired (sequential) samples obtained in CP and also at BC phase were available for 12 of the CML patients. Altogether, 27 regions of UPD 43 Mb were identified in these paired samples (Supplementary Table 4 ). Paired samples were also analyzed according to whether regions of UPD were only seen in BC phase. Two regions of UPD 43 Mb were identified only in the BC phase (Supplementary Table 5 ). Following on from the recent publication of common mutations of the ASXL1 gene in other myeloproliferative disorders (MPDs), 18 we looked for UPDs smaller than our standard cutoff of 43 Mb at the 20q11 region. We found a 0.5 Mb UPD in one patient (both in CP and BC phases) at 20q11, which encompasses the ASXL1 gene.
Copy number changes
Regions of copy number gain and loss 43 Mb were recorded. The copy number changes (CNCs) were identified in 4 of 21 BC samples and no CNC were identified in CP samples. Five regions of copy number gain (Table 2) , including one patient (5b) with an apparent trisomy 8 were identified. The remaining four regions of copy number gain were all seen in Patient 40 and were observed on chromosomes 9, 17 and 22 and ranged from 7.93 to 56.36 Mb.
A total of five regions of copy number loss (Table 3) were observed in a total of three patients on chromosomes 12, 16 and 17 and ranged from 20.12 to 33.88 Mb. All the copy number losses were identified in BC samples and were not observed in the paired CP samples. Common regions of copy number loss were identified in two patients in the BC phase at 17p13.3-p11.2 and at 12p13.3-p12.2. Copy number changes and LOH in CML J Boultwood et al
In addition, some smaller regions of CNC were recorded (o3 Mb). One patient (patient 41) showed a small deletion (B1 Mb) encompassing the IKAROS gene. We also observed two recurrent regions of copy number gain o3 Mb. These regions were identified at 3q25.33 and 8q23.1, and were relatively frequent in the CML patient group (both being identified in at least five CML patients). Table 4 shows two regions of recurrent copy number gain and the genes that map to that area.
Mutational analysis
Two cases (patients 12 and 40) were identified with a deletion at 17p13.3-p11.2 encompassing the TP53 gene. We carried out mutational analysis of the TP53 gene in the CP and BC samples of these cases (with the exception of patient 40 from whom only a BC sample was available). A known A4G mutation in exon 5 (K132R) of the TP53 gene 22 was observed in patient 12 in the BC, but not CP sample. The one other case (patient 40) did not show mutation of TP53. Two cases (20a and 41) were identified, one with a region of UPD and one with a deletion at 7p13-q11.21, a region containing the IKAROS gene. We carried out mutational analysis of the IKAROS gene in these cases, but no mutations were detected. In addition, we carried out mutational analysis of exon 12 of the ASXL1 gene in all the CML cases and we found ASXL1 mutations in 6 of 41 cases (Table 5) . Five patients had a frameshift mutation and one patient had a nonsense mutation. In addition, three cases had substitutions that we did not take into account as they could represent polymorphisms ( Table 5 ). The mutations were identified in patient samples from both CP and BC. However, in one positive case for which we had paired samples available (2a and b), we observed a nonsense mutation of ASXL1 in the BC sample, but not in the CP sample. None of the ASXL1 mutations identified in the patients with CML were identified in the DNA extracted from the peripheral blood samples of 111 normal individuals that were also sequenced, or are recorded in the NCBI entrez human SNP database.
Discussion
We have analyzed a group of 41 patients with CML by SNP array analysis for the presence of CNCs and loss of heterozygosity. All the CML samples used in this study were obtained before the widespread adoption of imatinib as treatment. Patients were studied at CP and BC to identify disease-related genomic abnormalities in CML and those related to disease progression.
We observed a total of 32 regions of UPD 43 Mb in 23 of 45 control subjects dispersed across the genome on 15/22 chromosomes. The frequency of regions of UPD in normal individuals observed in this and our previous study is comparable with that observed by other groups, including the study by Gibson et al. 21 These studies show that homozygous tracts are common in normal individuals and that a control pool is essential for the analysis of SNP array data. In this study, we report only those regions of UPD not observed in any of our group of 45 normal controls or in normal healthy control subjects reported in the literature by others. 20, 21 SNP analysis that enables the detection of UPD has already proven very informative in the study of myeloid malignancies. 20, 23, 24 For example, up to 20% of cases of acute myeloid leukemia (AML) have been found to have large-scale cryptic regions of acquired homozygosity in the form of UPD. 24 Subsequently, an impressive association between UPD and homozygous gene mutation in AML was determined. 23 By Abbreviations: BC, blast crisis; CML, chronic myeloid leukemia. Abbreviation: CML, chronic myeloid leukemia. Copy number changes and LOH in CML J Boultwood et al analogy with AML and myelodysplasia, SNP analysis may illuminate the location of disease genes in CML. For the patient group as a whole, we have determined disease-related UPD on the basis of size (43 Mb) and also the absence of the corresponding UPD in control groups. We find that regions of UPD are very common in both CP and BC patient groups. A total of 65 regions of UPD 43 Mb were detected in 30 of 41 CML patients dispersed on 17/22 chromosomes. Thus the frequency of UPD 43 Mb in CML is considerably greater (by approximately twofold) than that observed in normal controls. In the CP samples, 44 regions of UPD 43 Mb were identified in 24 of 32 patients. In the BC samples, 21 regions of UPD 43 Mb were identified in 13 of 21 patients. The regions of UPD are not evenly distributed across the various chromosomes. In both CP and BC patients, chromosome 8 had the highest frequency of UPD regions, with chromosomes 2 and 4 also showing a high frequency of UPD.
Eight regions of UPD 43 Mb were identified in two or more cases in CP and BC patients and are thus considered recurrent abnormalities: two different regions on 2q, one region on 4p, one on 7q, one region on 8p and two different regions on 8q, and one region on 12p.
Three recurrent regions of UPD were observed on chromosome 8 and this chromosome showed the highest frequency of recurrent UPD regions. The UPD at 8p23.1 was found in two CML patients and contains several genes of interest including MFHAS1 (MASL1), 25, 26 TNKS and SOX7. 27, 28 We have previously shown that TNKS (tankyrase), a TRF1-interacting factor that has an important role in the control of telomere dynamics, is upregulated in CP and accelerated phase CML. 10 The UPD at 8q11 was found in two CML patients. The most frequent UPD on chromosome 8 at 8q23, occurring in five patients, contained no known genes. Our demonstration of frequent regions of UPD on chromosome 8 in CML is intriguing given the strong association of abnormalities of chromosome 8 with disease progression in this disorder. 29, 30 Indeed, trisomy 8 is the most common secondary chromosomal aberration in CML, occurring in 34% of cases with additional changes. 8 The importance of trisomy 8 in the pathogenesis of CML has been long recognized, but the causative gene(s) mapping to chromosome 8 has remained elusive. 12 It is possible that the regions of UPD on chromosome 8 identified by our study give the location for genes of importance in the pathogenesis of CML.
Two recurrent regions of UPD were observed on the long arm of chromosome 2. The UPD at 2q21-q22 was found in three CML patients and contains several genes of interest including MCM-6 31 and CXCR4. CXCR4 is a chemokine receptor known to be downregulated in CML by BCR-ABL and this is associated with cell-migration defects in CML. 32, 33 The UPD at 2q32-q33 was found in two CML patients and contains the zinc transporter ZIP10 (SLC39A10). 34 A recurrent region of UPD was observed on chromosome 7. Interestingly, the UPD at 7q22 encompasses a commonly deleted region previously identified in a range of malignant myeloid disorders by Le Beau and colleagues. 35 The 7q22 commonly deleted region contains several candidate genes including FBXL13 and LRRC17.
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A UPD at 12p11.21-q12 was found in two CML patients and contains the DNM1L and PKP2 genes. DNM1L (DRP1) mediates caspase-independent apoptosis in CLL 36 and PKP2 is frequently overexpressed in malignancy. 37, 38 Paired samples obtained in both CP and BC phase were available for a proportion of CML patients (12 patients) included in this study. In these cases, two regions of UPD 43 Mb on chromosomes 2 and 8, respectively, were identified only in the BC phase in two patients and are thus associated with disease evolution in these individual CML patients.
In addition, a small UPD at 20q11, which encompasses the ASXL1 gene, a putative tumor suppressor, was found in one patient in both the CP and BC phases. Most recently, heterozygous frameshift mutations of exon 12 of the ASXL1 have been reported in 11% of patients with myelodysplasia 19 and in B7% patients with the MPD essential thrombocythemia and primary myelofibrosis. 18 Thus, we chose to sequence exon 12 of the ASXL1 gene in our group of patients with the MPD CML. We identified mutations of ASXL1 in 6 of 41 patients. Five of these mutations were frameshift mutations and the other was a nonsense mutation. The mutations were identified in patient samples from both CP and BC. Thus, this gene mutation can represent an early event in CML, which is intriguing given the rarity of gene mutations (other than the BCR/ABL) in CP. The function of the human ASXL1 protein is poorly understood, but there is some evidence to suggest that it may represent a component of DNA-and/or histone-modifying complexes.
39
ASXL1 belongs to a family of three members that encode proteins belonging to polycomb and mixed lineage leukemia/ trithorax chromatin modifier complexes. 39 ASXL1 is a fusion partner of PAX5 in acute lymphoblastic leukemia. 40 In this study, we have shown, for the first time, that mutation of ASXL1 is a frequent event in CML, adding further weight to the proposal that mutation of ASXL1 may have an important role in the pathogenesis of MPD.
The BC stage of CML is commonly associated with nonrandom secondary chromosomal changes that, in addition to the t(9;22), include þ Ph, þ 8, i(17q), þ 19, t(3;21)(q26;q22) and t(7;11)(p15;p15). 8 These karyotypic changes involve the loss or gain of large chromosomal regions together with the concomitant loss of tumor suppressor genes and/or gain of oncogenes. However, the molecular mechanisms responsible for disease progression in CML are not fully understood. 3, 30 Ten regions of copy number gain or loss 43 Mb were observed in 4 of 21 BC samples and none were observed in the CP samples. Thus, the CNC observed in this study are clearly associated with disease evolution and most probably reflect increased genomic instability in BC CML. Regions of copy number loss were identified on chromosomes 12, 16 and 17, two of which were recurrent. One region of copy number loss at 17p13.3-p11.2, encompassing the TP53 gene, was identified in two patients. The loss of 17p, due to i(17q), -17, or other changes resulting in 17p-is frequently reported in BC CML and is often associated with mutation of the TP53 gene. 11, 12 We therefore carried out mutational analysis of the TP53 gene in the two cases showing loss of 17p13.3-p11.2 and one patient had a TP53 mutation in the BC but not CP phase of the disease. A region of copy number loss at 12p13.33-p12.2 was found in two patients in BC. This recurrent region contains many genes known to have a role in carcinogenesis including JARID1A, WNK1, FOXM1, ECR1 and NOL1. Intriguingly, 12p13 is a chromosomal region often involved in structural rearrangements in BC CML. 8 In addition, one patient showed a small deletion (B1 Mb) encompassing the IKAROS gene. We carried out mutational analysis of the IKAROS gene in this case, but no mutations were detected. The regions of CNC identified in this study were found only in BC CML and therefore may give the location for novel genes of importance in disease evolution in CML.
In addition, we observed two recurrent regions of copy number gain that were smaller than 3 Mb and occurred relatively frequently in the patient group under investigation and were found in both CP and BC phases. One of these amplified regions mapped to chromosome 8 at 8q23, and was found in five patients. The amplified region at 8p23 overlaps with a recurrent amplicon found in esophageal adenocarcinoma and contains several genes known to have a role in carcinogenesis including the CTSB gene. 41, 42 Interestingly, Gribble et al.
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, using metaphase CGH, have demonstrated the amplification of the 8q23/q24 region in six of eight CML-derived cell lines. 29 More recently, Hosoya et al., 30 revealed a number of novel CNCs involving chromosome 8 in some patients with CML using array CGH. These alterations included a gain at 8p23.2.
It is desirable for SNP studies such as those reported here to include constitutional controls. However, this study was conducted with archival DNA samples collected in the 'pre-imatinib' era and so this did not prove to be feasible. Nevertheless, it is clear that the differences in the frequency of UPDs between patients and controls are significant. For example, the chromosome 8 UPDs are far more common in the patient group than in controls. It should also be noted that this particular study more closely approximates to the natural history of disease progression in CML than a contemporaneous study would. The evolution of CML in the present era includes elements possibly not relevant in the pre-imatinib era such as kinase domain mutations of BCR-ABL, but nonetheless it is always important to try and establish the natural pattern of disease progression.
To our knowledge this study represents the first SNP array analysis of CML yet reported. We have identified several recurrent regions of UPD in patients with CML, which may be of pathogenetic importance and may underlie the clinical heterogeneity observed in this disorder. Our demonstration of frequent mutation of ASXL1, a putative tumor suppressor gene, likely represents an important new molecular abnormality in CML. We have also shown that BC CML is associated with an increase in CNC. In particular, this study has demonstrated overrepresentation of genomic aberrations (recurrent UPD and copy number gain) mapping to chromosome 8 in CML. The role of chromosome 8 in CML deserves further study, and our study provides a starting point for a range of future investigations.
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